OncoMatch/Clinical Trials/NCT05945875
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
Is NCT05945875 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Panitumumab-IRDye800 for head and neck squamous cell carcinoma.
Treatment: Panitumumab-IRDye800 — This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery (intraoperative), to detect disease in patients with head and neck cancer. 111In-panitumumab is an imaging agent made of a monoclonal antibody that has been labeled with a radioactive molecule called indium In 111. The agent targets and binds to receptors on tumor cells. This allows the cells to be visualized and assessed with SPECT/CT imaging techniques. SPECT is special type of CT scan in which a small amount of a radioactive drug is injected into a vein and a scanner is used to make detailed images of areas inside the body where the radioactive material is taken up by the cells. CT is an imaging technique for examining structures within the body by scanning them with x-rays and using a computer to construct a series of cross-sectional scans along a single axis. Panitumumab-IRDye800 is an imaging agent composed of panitumumab, a monoclonal antibody, linked to a fluorescent dye called IRDye800. Upon administration, panitumumab-IRDye800 targets and binds to receptors on tumor cells. This allows the tumor cells to be detected using fluorescence imaging during surgery. Adding 111In-panitumumab SPECT/CT imaging to intraoperative panitumumab-IRDye800 fluorescence imaging may be more effective at detecting disease in patients with head and neck cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Lab requirements
Blood counts
Hemoglobin >= 9 gm/dL; White blood cell count > 3000/mm^3; Platelet count >= 100,000/mm^3
Kidney function
Serum creatinine <= 1.5 times upper reference range; severe renal disease or anuria [excluded]
Liver function
significant liver disease within 6 months prior to enrollment [excluded]
Cardiac function
Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment [excluded]; Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females); Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents [excluded]
Hemoglobin >= 9 gm/dL; White blood cell count > 3000/mm^3; Platelet count >= 100,000/mm^3; Serum creatinine <= 1.5 times upper reference range; significant liver disease within 6 months prior to enrollment [excluded]; severe renal disease or anuria [excluded]; Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); or unstable angina within 6 months prior to enrollment [excluded]; Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females); Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanderbilt University/Ingram Cancer Center · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify